Greece
Genepharm SA, known as "The Greek Global Pharmaceutical Company", has been a prominent figure in the pharmaceutical industry since its founding in 1971. Catering to the expansive markets of over 90 countries, this Greece-based company specializes in the development, production, and distribution of certified generic pharmaceutical products.
Operating from its privately owned facility in Pallini, Attica, spanning 15,000 m2, Genepharm boasts two state-of-the-art production lines adhering to European specifications (EU GMPs). These lines are dedicated to manufacturing both conventional and oncological solids, marking its significant expertise in therapeutic categories such as cardiology, diabetes, oncology, urology, and antipsychotic treatments.
Despite its extensive global reach and impressive production capacity—500 million tablets and 40 million capsules in solid conventional, and 140 million tablets and 10 million capsules in solid oncology—there is no reported recent investment or investor information, highlighting an opportunity for strategic partnerships and investment input to capitalize on further growth and innovation in a competitive industry.
